Abstract
The effects of β-cyclodextrin (β-CyD) and trehalose on glycation of human serum albumin (HSA) were studied. These additives reduced AGEs and nanofibril formation of HSA under in vitro glycation conditions and improved its helical structure. These were accomplished through direct interactions of them with HSA and alterations in solute-protein interactions.
Keywords: Diabetes, trehalose, β-cyclodextrin, glycation, HSA, glucose
Protein & Peptide Letters
Title: Inhibitory Effects of β-Cyclodextrin and Trehalose on Nanofibril and AGE Formation During Glycation of Human Serum Albumin
Volume: 16 Issue: 6
Author(s): Esmaeel Sharifi, Naghmeh Sattarahmady, Mehran Habibi-Rezaei, Mohammad Farhadi, Nader Sheibani, Faizan Ahmad and Ali Akbar Moosavi-Movahedi
Affiliation:
Keywords: Diabetes, trehalose, β-cyclodextrin, glycation, HSA, glucose
Abstract: The effects of β-cyclodextrin (β-CyD) and trehalose on glycation of human serum albumin (HSA) were studied. These additives reduced AGEs and nanofibril formation of HSA under in vitro glycation conditions and improved its helical structure. These were accomplished through direct interactions of them with HSA and alterations in solute-protein interactions.
Export Options
About this article
Cite this article as:
Sharifi Esmaeel, Sattarahmady Naghmeh, Habibi-Rezaei Mehran, Farhadi Mohammad, Sheibani Nader, Ahmad Faizan and Moosavi-Movahedi Akbar Ali, Inhibitory Effects of β-Cyclodextrin and Trehalose on Nanofibril and AGE Formation During Glycation of Human Serum Albumin, Protein & Peptide Letters 2009; 16 (6) . https://dx.doi.org/10.2174/092986609788490212
DOI https://dx.doi.org/10.2174/092986609788490212 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
CNS & Neurological Disorders - Drug Targets Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Anti-Inflammatory Agents in Parkinsons Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia CypD: The Key to the Death Door
CNS & Neurological Disorders - Drug Targets Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology The Clinical Relevance of Advanced Glycation Endproducts (AGE) and Recent Developments in Pharmaceutics to Reduce AGE Accumulation
Current Medicinal Chemistry